Patrick B.
- Country
- Belgium
- Department
- Gastro-Enterology
Research Overview
- A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumab in Pediatric Clinical Study Participants (2 to <18 Years of Age)
- A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab with Open-Label Induction, Randomized Double-Blind Maintenance, and Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) with Moderately to Severely Active Crohn's Disease
- Evaluation of Filgotinib Efficacy, Safety, and Pharmacokinetics in Pediatric Patients with Moderate to Severe Ulcerative Colitis
Data & Insights
Has run more than one trial at 63 of 229 partner sites.
Specializations
Pediatric Inflammatory Bowel Disease
The investigator specializes in treating moderately to severely active inflammatory bowel conditions in pediatric populations. Their expertise encompasses comprehensive management of both Crohn's Disease and Ulcerative Colitis in children and adolescents.
- Pediatric Crohn's Disease Management
- Pediatric Ulcerative Colitis Treatment
- Advanced Biologic Therapies
The investigator's work focuses on evaluating innovative therapeutic approaches for young patients who have shown inadequate response to conventional treatments.
Novel Therapeutic Applications
This clinician investigates multiple targeted immunological treatments including ustekinumab, upadacitinib, and risankizumab. Their research extends to studying oral therapeutic options such as ozanimod, filgotinib, and tofacitinib for pediatric patients.
- Intravenous Induction Treatments
- Subcutaneous Maintenance Therapy
- Long-term Treatment Outcomes
Their work emphasizes both immediate therapeutic efficacy and sustained clinical improvements in pediatric populations.
Special Clinical Interests
The investigator has particular expertise in treating juvenile inflammatory conditions, including juvenile psoriatic arthritis alongside inflammatory bowel diseases. Their approach encompasses comprehensive evaluation of clinical remission and endoscopic response.
- Treatment-Resistant Cases
- Multi-System Inflammatory Conditions
- Long-term Disease Management
Their research includes pharmacokinetic studies and safety assessments in pediatric populations aged 2 to 18 years.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.